ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Adaptive Biotechnologies Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$23.95−0.07 (-0.29%)

Close on Oct 19, 2026

Market cap: $3.83B
P/E (TTM): –
Dividend yield: –

Adaptive Biotechnologies Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	277	179	170	185	154	98	85	56	38
Cost of Revenue	71	72	76	58	49	23	22	20	16
Gross Profit	206	107	95	127	105	76	63	36	23
Research & Development	94	103	122	142	142	116	71	39	32
Selling, General & Admin	167	158	173	184	170	111	69	45	33
Selling & Marketing	95	85	89	96	95	61	38	24	17
General & Administrative	73	73	84	89	75	50	30	20	16
Advertising Expenses	4.10	6.10	8.60	14	22	15	6.60	3.50	1.80
Total Costs & Expenses	334	342	397	385	363	251	163	105	83
Operating Income	-57	-163	-227	-200	-209	-153	-78	-50	-44
Interest Expense	12	12	14	4.24	–	–	–	–	–
Merger & Restructuring Charges	–	2.00	–	2.02	–	–	–	–	0.84
Asset Impairment Charges	0	7.21	25	0	0	0	0	0.02	0.19
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	-0.32	0.04	-0.13
Pretax Income	-59	-160	-225	-200	-207	-146	-69	–	–
Income Tax Expense	0	0	0	–	–	–	0	–	–
Net Income incl. Noncontrolling Interests	-59	-160	-225	-200	-207	-146	-69	-46	-43
Minority Interest in Earnings	0.04	-0.10	-0.05	-0.18	-0.02	–	–	–	–
Net Income	-59	-159	-225	-200	-207	-146	-69	-46	-43
Net Income to Common	–	–	–	–	-207	-146	-70	-46	-43
EPS (Basic)(per share)	-0.39	-1.08	-1.56	-1.40	-1.48	-1.11	-1.01	-3.67	-3.50
EPS (Diluted)(per share)	-0.39	-1.08	-1.56	-1.40	-1.48	-1.11	-1.01	-3.67	-3.50
Shares Outstanding (Basic, Weighted)(shares)	152	147	144	143	140	131	69	13	12
Shares Outstanding (Diluted, Weighted)(shares)	152	147	144	143	140	131	69	13	12
EBITDA	-41	-145	-207	-179	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 75.6%
Operating margin: -12.2%
Net margin: -20.7%
Return on equity, FY2025: -28.2%

Financial strength

Current ratio: 4.79
Debt to equity: 0.00
Debt to assets: 0.0%
Cash to current liabilities: 193.7%

Valuation

P/E ratio: –
Price to sales: 12.43
Price to book: 26.79
Dividend yield: –